Aurinia Pharmaceuticals Inc $AUPH Shares Acquired by IFP Advisors Inc

IFP Advisors Inc grew its position in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) by 10.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 361,634 shares of the biotechnology company’s stock after acquiring an additional 33,843 shares during the quarter. IFP Advisors Inc’s holdings in Aurinia Pharmaceuticals were worth $6,137,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the company. Allworth Financial LP increased its position in shares of Aurinia Pharmaceuticals by 34.9% during the second quarter. Allworth Financial LP now owns 3,307 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 855 shares in the last quarter. Nykredit A S purchased a new position in Aurinia Pharmaceuticals in the 2nd quarter valued at $35,000. Allianz Asset Management GmbH acquired a new stake in Aurinia Pharmaceuticals during the 2nd quarter worth $14,284,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Aurinia Pharmaceuticals during the 2nd quarter worth $1,927,000. Finally, California State Teachers Retirement System grew its holdings in shares of Aurinia Pharmaceuticals by 2,033.2% during the second quarter. California State Teachers Retirement System now owns 2,264,799 shares of the biotechnology company’s stock worth $38,434,000 after buying an additional 2,158,630 shares in the last quarter. 36.83% of the stock is owned by institutional investors and hedge funds.

Aurinia Pharmaceuticals Stock Up 1.1%

Shares of AUPH opened at $16.25 on Thursday. Aurinia Pharmaceuticals Inc has a 52-week low of $10.34 and a 52-week high of $19.25. The company has a market capitalization of $2.16 billion, a PE ratio of 7.10 and a beta of 1.40. The stock has a fifty day simple moving average of $15.79 and a two-hundred day simple moving average of $15.60. The company has a quick ratio of 4.97, a current ratio of 5.42 and a debt-to-equity ratio of 0.07.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.24 by $0.04. The business had revenue of $58.57 million for the quarter, compared to analyst estimates of $80.45 million. Aurinia Pharmaceuticals had a return on equity of 26.11% and a net margin of 100.84%. As a group, equities analysts forecast that Aurinia Pharmaceuticals Inc will post 0.79 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Bloom Burton upgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 20th. Weiss Ratings raised shares of Aurinia Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 26th. Zacks Research cut shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 21st. Wall Street Zen downgraded shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Finally, Royal Bank Of Canada raised their target price on shares of Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the stock a “sector perform” rating in a research note on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, Aurinia Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $17.67.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.